Evidence map›Paper›PMID 25034079›Full record

ArticleMolecular oncology2014

The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin.

Melissa S Simper, Joyce E Rundhaug, Carol Mikulec, Rebecca Bowen, Jianjun Shen, Yue Lu, Kevin Lin, Inok Surh, Susan M Fischer

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Eicosanoids in Cancer: Prostaglandin EFrontiers in pharmacology · 2020
    Review
  5. Review
  6. Expression of prostaglandin EInternational ophthalmology · 2018
    Article
  7. Article
  8. Review
  9. Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Melissa S SimperThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Joyce E RundhaugThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Carol MikulecThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Rebecca BowenThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Jianjun ShenThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Yue LuThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Kevin LinThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Inok SurhThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Susan M FischerThe Department of Molecular Carcinogenesis, Science Park, PO Box 389, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA. Electronic address: smfischer@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
COX-2 in Skin CarcinogenesisR01CA100140 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FISCHER, SUSAN M · 2003 to 2007
$1.7M
NCI NIH HHS CA100140NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA16672-30NCI NIH HHS R01 CA100140PHS HHS RP120348
6 · The paper itself

Abstract

To determine whether the EP4 receptor for prostaglandin E2 (PGE2) contributes to the tumor promoting activity of PGs in murine skin, EP4 over-expressing mice (BK5.EP4) were generated and subjected carcinogenesis protocols. An initiation/promotion protocol resulted in 25-fold more squamous cell carcinomas (SCCs) in the BK5.EP4 mice than wild type (WT) mice. An increase in SCCs also occurred following treatment with initiator alone or UV irradiation. The initiator dimethylbenz[a]anthracene caused cytotoxicity in BK5.EP4, but not WT mice, characterized by sloughing of the interfollicular epidermis, regeneration and subsequent SCC development. A comparison of transcriptomes between BK5.EP4 and WT mice treated with PGE2 showed a significant upregulation of a number of genes known to be associated with tumor development, supporting a pro-tumorigenic role for the EP4 receptor.

Indexed as

AnimalsInterleukinsMiceMice, TransgenicReceptors, Prostaglandin E, EP4 SubtypeSkin NeoplasmsWound Healinginterleukin 20InterleukinsReceptors, Prostaglandin E, EP4 SubtypeEP4 receptorMurine skinProstaglandin E(2)Skin tumorsTumor promotion

Identifiers

PMID25034079
PMCPMC4253556
OpenAlexW2097933072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.